**Fig 1.1****Identification of naturally occurring metal-ion binding site in the 7TM leukotriene LTB<sub>4</sub> receptor**


Whole cell competition binding experiment with COS-7 cells expressing the wild type and mutant variants of the leukotriene LTB<sub>4</sub> receptor using [<sup>3</sup>H]-LTB<sub>4</sub> as the radioligand.

Panel A. Affinity of Cu(II), 2,2'-bipyridine and the complex thereof in the wild type LTB<sub>4</sub> receptor.


Panel B. Affinity of Cu(bipyridine) in mutant forms of the LTB<sub>4</sub> receptor in which the metal-ion binding is severely impaired.

Panel C. Helical wheel diagram illustrating the transmembrane segments of the LTB<sub>4</sub> receptor. The two cysteine residues within the transmembrane segment III which have been identified as critical for metal-ion chelator complex binding, Cys93 and Cys97 are indicated in dark gray.

A.



B.


**Fig 1.2****Identification of naturally occurring metal-ion binding site in the 7TM galanin receptor**

Whole cell competition binding experiment with COS-7 cells expressing the wild type and mutant forms of the galanin receptor using [ $^{125}$ I]-galanin as radioligand.


Panel A. Affinity of the free copper metal-ion, the free chelator and the phenanthroline complex on the wild-type galanin receptor.

Panel B. Affinity of the copper-phenanthroline complex on two mutant forms of the galanin receptor, in which the binding of the metal-ion complex is impaired.

A.



B.



C.




Fig 1.3

### Identification of naturally occurring metal-ion binding site in the 12TM protein, the dopamine transporter.

Competition analysis of uptake of  $[^3\text{H}]$ -dopamine in whole COS-7 cells expressing the dopamine transporter.

Panel A. Uptake of  $[^3\text{H}]$ -dopamine by the wild-type dopamine transporter in the presence of free metal zinc-ion and zinc in complex with the chelator 2,2'-bipyridine.


Panel B. Dopamine uptake analysis in a mutant form of the dopamine transporter, [H193K], in which binding of the metal-ion complex has been eliminated (Noregaard et al. EMBO J. (1998) 17: 4266-4273).

Panel C. Effect of metal-ion complex formation on the ability to inhibit  $[^3\text{H}]$ -dopamine uptake in the wild-type and [H193K] mutant dopamine transporter. (For compounds, 209 and 210, see list of compounds in Appendix).

A.

		Ions		1,10-Phenanthroline-complexes		2,2'-Bipyridine-complexes	
		Zn $\pm$ SEM (n)	Cu $\pm$ SEM (n)	Zn $\pm$ SEM (n)	Cu $\pm$ SEM (n)	Zn $\pm$ SEM (n)	Cu $\pm$ SEM (n)
WT hNK1		320 $\pm$ 20 (5)	370 $\pm$ 30 (5)	490 $\pm$ 50 (4)	480 $\pm$ 60 (3)	390 $\pm$ 60 (4)	150 $\pm$ 30 (2)
Y92H	II:24;III:04	17 $\pm$ 3 (3)	28 $\pm$ 5 (2)	26 $\pm$ 5 (2)	28 $\pm$ 6 (3)	31 $\pm$ 5 (3)	25 $\pm$ 3 (2)
E163H:N109H	III:05;V:01	13 $\pm$ 5 (2)	120 $\pm$ 20 (2)	46 $\pm$ 8 (2)	120 $\pm$ 20 (2)	13 $\pm$ 4 (2)	180 $\pm$ 30 (2)
P112H:M291C	III:06;VII:06	41 $\pm$ 9 (8)	82 $\pm$ 15 (2)	63 $\pm$ 4 (5)	45 $\pm$ 12 (4)	21 $\pm$ 2 (4)	13 $\pm$ 2 (4)
Y272H	V:05;VI:24	9.1 $\pm$ 1 (3)	330 $\pm$ 50 (3)	8.8 $\pm$ 1.2 (3)	150 $\pm$ 20 (2)	9.8 $\pm$ 3.2 (2)	140 $\pm$ 20 (2)

B.



C.




Fig II.1


Binding of various metal-ion complexes to a library of inter-helical metal-ion sites engineered into the tachykinin NK1 receptor.

COS-7 cells expressing various engineered forms of the NK1 receptor were analyzed by competition binding using [ $^{125}$ I]-Substance P as radioligand.

Panel A. IC<sub>50</sub> values for the zinc and copper metal-ions and complexes thereof with the chelators, 2,2'-bipyridine and phenanthroline are presented in the table. N indicated the number of experiments performed.


Panel B. Data obtained using the chelator cyclam are presented for the NK1 mutant in which an inter-helical metal-ion site has been generated through the introduction of the HisV:05;HisVI:24 exchanges.

Panel C. A helical diagram representing the four sets of inter-helical metal-ion sites which appear in Panel A are indicated.




**Fig 11.2 Re-engineering of a metal-ion chelator binding site in the 12<sup>TM</sup> dopamine transporter.** Dopamine uptake was analysed in COS-7 cells expressing the wild type and mutant forms of the dopamine transporter in competition with the metal-ion chelator complex, zinc(II)-2,2'-bipyridine. The two panels show two forms of re-engineered dopamine transporters in which the ability to bind the metal-ion chelator complexes have been reconstituted following the elimination of the His193 interaction point.

A.



B.

**Fig III.1**




**Structure-activity relationship of antagonist metal-ion complexes in the galanin and the leukotriene LTB<sub>4</sub> receptors.**

Panel A. Competition binding analysis in COS-7 cells expressing the galanin receptor. Binding of [ $^{125}$ I]-galanin was analysed in the presence of various copper-ion chelator complexes.



Panel B. Competition binding analysis in COS-7 cells expressing the LTB<sub>4</sub> receptor. Binding of [ $^3$ H]-LTB<sub>4</sub> was analysed in the presence of various copper-ion chelator complexes.

For structures of the chelators employed in both panels, see Appendix.

A.




B.

**Figur III.2**


**Structure-activity relationship of antagonist metal-ion complexes in the metal-ion site engineered tachykinin NK1 receptor**

Binding of [ $^{125}$ I]-Substance P was analysed in COS-7 cells expressing NK1 receptor which have been engineered to bind the zinc metal-ion. Ligand binding is presented in competition with the zinc metal-ion, the zinc-1,10-phenanthroline complex and with other zinc-chelator complexes as indicated. For structures of the chelators, see Appendix.


A.



B.



C.



Figur III.3

Structure-activity relation ship of agonistic metal-ion complexes in the metal-ion site

Beta2-adrenergic receptor.


The effect of Cu(II) and copper-chelator complexes on stimulation of accumulation of intracellular cAMP was analyzed in COS-7 cells expressing the beta2-adrenoceptor.

Panel A. Washing experiment demonstrating the reversibility of the stimulatory action of the metal-ion complexes.

Panel B. The effect of copper and complexes in the wild-type beta2-AR and in engineered forms of the receptor.


Panel C. Dosis-response analysis of selected copper-chelator complexes on the [F289C;N312C] beta2-AR.



**Figur III.4**

**Structure-activity relationship of antagonistic metal-ion complexes in a soluble protein, the enzyme FVIIa.**

A comparison of selected metal-ion complexes on the binding of [<sup>3</sup>H]-LTB<sub>4</sub> and the inhibition of the enzymatic activity of the active form of Factor VII (FVIIa) in COS-7 cells expressing respectively the LTB<sub>4</sub> receptor (Panel B) and the FVIIa (Panels A and C). For structure of the chelators see the Appendix.




**Figur III.5**










**Structure-based optimization of metal-ion chelators for secondary interactions in the CXCR4 receptor and other biological targets.**

Helical wheel diagram for the CXCR4 receptor. The Asp171 residue present in the transmembrane segment IV, and which is considered a major attachment site for the binding of the cyclam chelator is shown in white on black. Positions which in combination are proposed to constitute putative metal-ion binding sites are high-lighted in pairs and in black on dark gray.

Compound	Structure	Name	Provider
62		1,10-Phenanthroline	Sigma
92		Dipyrindine	Sigma
60		Cyclam	Aldrich
80		2-(isoquinoline-3-yl)-4-(5-phenyl-oxazol-2-yl)-quinoline	ChemDiv Inc.
83		2,2'-di(4-(N,N-(2-hydroxyethyl)carboxamide)quinoline)	ChemDiv Inc.
85		2,2'-di(4-(benzimidazol-2-yl)-quinoline)	ChemDiv Inc.
133		2,9-dimethanol-1,10-phenanthroline	Sigma-Aldrich
134		5-phenyl-1,10-phenanthroline	Sigma-Aldrich
135		2,9-bis(trichloromethyl)-1,10-phenanthroline	Sigma-Aldrich
175		1,10-phenanthroline-5,6-dione	Aldrich
176		5-methyl-1,10-phenanthroline	Sigma
180		4,4'-Di-tert-butyl-2,2'-dipyridyl	Aldrich
183		Dipyrido[3,2-a:2',3'-c]phenazine hemhydrate	ABCR GmbH & Co
209		2-pyridylamidoxime	TTM Pharma
210		2-pyridylamidoxime, O-acetyl	TTM Pharma



Figur IV

	Metal ion	Log K <sub>1</sub>	Log K <sub>2</sub>	Log K <sub>3</sub>
	Co <sup>2+</sup>	6.4	11.3	16.6
	Co <sup>2+</sup>	5.8	11.3	16.0
	Ni <sup>2+</sup>	7.0	13.9	16.6
	Zn <sup>2+</sup>	5.3	9.6	13.3
	Cu <sup>2+</sup>	8.1	13.6	17.0
	Zn <sup>2+</sup>	2.8	5.2	
	Cu <sup>2+</sup>	5.1		
	Zn <sup>2+</sup>	7.6	12.1	
	Zn <sup>2+</sup>	5.0	9.4	12.7
	Cu <sup>2+</sup>	7.4	13.8	
	Zn <sup>2+</sup>	6.6	12.6	18.3
	Cu <sup>2+</sup>	8.6	15.0	20.0
	Zn <sup>2+</sup>	4.1	7.7	19.1
	Cu <sup>2+</sup>	5.2	11.0	
	Zn <sup>2+</sup>	4.1	7.8	9.5

Figur V